000			03176cam a2200349 a 4500
003			EG-GiCUC
005			20250223032616.0
008			201019s2020 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.10.M.Sc.2020.Es.R
100	0		_aEsraa Mahmoud Mohamed Mahmoud
245	1	4	_aThe role of dermoscopy in assessment of vitiligo stability and the relation of dermoscopic signs of vitiligo to serum levels of CXCL10 / _cEsraa Mahmoud Mohamed Mahmoud ; Supervised Rehab Ali Abdesalam Hegazy , Dina Mohamed Gamaleldin Saadi , Laila Ahmed Rashed Ismail
246	1		_aبالدم CXCL10 دور الديرموسكوب فى تقييم مرض البهاق و العلاقة بين علامات مرض البهاق بالديرموسكوب و مستوى
260			_aCairo : _bEsraa Mahmoud Mohamed Mahmoud , _c2020
300			_a95 P. : _bcharts , facsmilies ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Dermatology and Venerology
520			_aBackground: Distinguishing vitiligo stability from activity appears to be crucial, especially for control of early progressive vitiligo as well as for surgical treatment. Although diagnosis of vitiligo is primarily clinical, certain non- invasive tests like dermoscopy are helpful especially in doubtful cases (in evolving disease), and for objective evaluation of treatment response. Furthermore, certain substances released in tissues and sera of vitiligo patients can assist in detection of vitiligo status such as; CXCL-10, a chemokine released in response to IFN-Þ, that represents an indicator of disease activity. Some studies identified a critical role for CXCL10 in both the progression and maintenance of vitiligo and thereby supported inhibiting CXCL10 as a targeted treatment strategy. Aim of work: We aim to detect the dermoscopic findings in active and stable vitiligo, and to correlate these findings with VIDA scores, clinical signs of activity and stability as well as CXCL10 serum levels. Patients and Methods: The study was conducted between March 2019 and March 2020. 97 clinically diagnosed vitiligo patients were enrolled and assessed using VIDA scores and clinical examination to detect signs of activity and stability in vitiligo. Further evaluation using dermoscopy was performed and dermoscopic scores were calculated by the use of the modified BPLeFoSK score. A blood sample was taken from each patient to measure serum CXCL10 by ELISA technique. Results: According to VIDA scores, 51.5% of the patients had active vitiligo while 48.5% had stable vitiligo. Clinically, 63.9% of the patients had active vitiligo while 36.1% had stable vitiligo
530			_aIssued also as CD
653		4	_aCXCL-10
653		4	_aVIDA
653		4	_aVitiligo
700	0		_aDina Mohamed Gamaleldin Saadi , _eSupervisor
700	0		_aLaila Ahmed Rashed Ismail , _eSupervisor
700	0		_aRehab Ali Abdesalam Hegazy , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aAmira _eCataloger
905			_aNazla _eRevisor
942			_2ddc _cTH
999			_c78313 _d78313